Eosinophilic gastrointestinal diseases (EGIDs) have been increasingly identified as a cause of stomach, intestine and esophagus disorders. To help clinicians, researchers and advanced practice providers better understand EGIDs, AGA and myCME® have put together Gastro Quest: EGIDs, an interactive and anatomical journey that highlights disease progression, mechanism of action for therapeutic agents, and various treatment strategies.
The interactive online module, developed by Evan Dellon, MD, MPH, AGAF, and Amanda Muir, MD, uses a 3D anatomy and disease software platform to guide learners on the pathogenesis, diagnosis and treatment of eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE).
During the course, worth 0.50 AMA PRA Category 1 Credits™, you will:
- Learn about the pathogenesis and disease progression of EGIDs
- Identify key steps and metrics for diagnosis aligned with available guidelines
- Discuss the mechanism of action for current and emerging treatment strategies
This activity is supported by independent medical education grants from Allakos Inc., Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme and Takeda Pharmaceuticals U.S.A., Inc.
